<
  GlycoNet Website    Support  

The following NCEs have contributed to the development of the Forum:
GRAND, AGE-WELL, GlycoNet, CFN

Difference between revisions of "Chronic Diseases:Information"

From GlycoNet Forum

(Created page with "[public] {{DISPLAYTITLE:Chronic Diseases: Developing new therapies for a variety of chronic diseases }} For decades we have known that an enzymatic process called glycosylatio...")
 
 
Line 1: Line 1:
 
[public]
 
[public]
{{DISPLAYTITLE:Chronic Diseases: Developing new therapies for a variety of chronic diseases }}
+
{{DISPLAYTITLE:Chronic Diseases: Developing novel treatments to rare genetic diseases }}
For decades we have known that an enzymatic process called glycosylation is abnormal in cancerous cells and other diseased human tissues, yet therapeutic strategies addressing this biochemical change have remained elusive. An attempt to modify the glycosylation process has become a new target for therapeutics. This theme will address a range of targets for human health by applying knowledge gained in glycomics over the last decade, with the aim to bridge the gap between fundamental advances and therapeutic applications in cancer, inflammation and cardiovascular disease.
+
Glycomics presents an opportunity to develop novel treatments for rare genetic diseases that arise from deficiencies in sugar metabolism, such as Gaucher’s disease and Fabyr’s disease. Understanding the biochemical and molecular basis of single gene disorders has led to therapeutic strategies for rare diseases and a realization that development of many common disorders involves altered molecular pathways identified in many rare diseases. Developing therapies for rare diseases thus potentially impacts common disorders.
 
[/public]
 
[/public]

Latest revision as of 18:55, 5 August 2015

Glycomics presents an opportunity to develop novel treatments for rare genetic diseases that arise from deficiencies in sugar metabolism, such as Gaucher’s disease and Fabyr’s disease. Understanding the biochemical and molecular basis of single gene disorders has led to therapeutic strategies for rare diseases and a realization that development of many common disorders involves altered molecular pathways identified in many rare diseases. Developing therapies for rare diseases thus potentially impacts common disorders.